15 news items
Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting
CADL
20 May 24
-2409, Candel's most advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus
Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection
ABVC
AMGN
CADL
15 May 24
the seamless Phase 2/3 master protocol design that will evaluate multiple investigational therapies for pancreatic cancer treatment. Thus, the intent
Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection
ABVC
AMGN
CADL
15 May 24
the seamless Phase 2/3 master protocol design that will evaluate multiple investigational therapies for pancreatic cancer treatment. Thus, the intent
Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb
AZN
CADL
HALO
9 May 24
and primary investigator of the GOBLET trial. "My experience to date with the GOBLET study, including the positive metastatic PDAC and encouraging anal
Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb
AZN
CADL
HALO
9 May 24
and primary investigator of the GOBLET trial. "My experience to date with the GOBLET study, including the positive metastatic PDAC and encouraging
f7calt5w3xg8etv04mnn3i2ikls7m
AZN
CADL
HALO
9 May 24
Dirk Arnold, M.D., Ph.D., Director of Asklepios Tumorzentrum Hamburg and primary investigator of the GOBLET trial
i2be7vno48uad497ywvpdu7q7o6njvc9dts6p5zcvfbfxy5rqg
AZN
CADL
HALO
9 May 24
Dirk Arnold, M.D., Ph.D., Director of Asklepios Tumorzentrum Hamburg and primary investigator of the GOBLET trial
w9wqpegdonz5ys0iv10emi4ivl9jxmpw
CADL
11 Apr 24
indication.About CAN-2409CAN-2409, Candel's most advanced multimodal biological immunotherapy candidate, is an investigational
ddht ne0afjgom9gb4bhok
CADL
9 Apr 24
improve anti-tumor immunity. The presentation describes the development of an investigational TLS-inducing multimodal therapeutic using the enLIGHTEN
o191jftz98ri4ko7c6zd72opp91icyttezd0rgl2ma4hnf88n
CADL
5 Apr 24
after standard of care (SoC) treatment.
The investigators observed a nearly doubling of the expected median overall survival (mOS
46ywukt4ss6stgxum 928acnoqhbrpj8ct6l3x7nl9kpr1oqjfrlq0
CADL
1 Apr 24
of CAN-3110 in recurrent high-grade glioma.
The investigators observed a nearly doubling of the expected median overall survival (mOS
27rawc95v43ame foh3hv4t2bsskna6eeaaomk350mou
CADL
28 Mar 24
investigational viral multimodal immunotherapies, as compared to standard of care, in non-small cell lung cancer (CAN-2409), pancreatic cancer (CAN-2409
2wo8yu
CADL
15 Mar 24
of Nestin in cancer cells. CAN-3110 is being evaluated in a phase 1b investigator-sponsored
w220m7bkcrsnw 4cpejl1rgxr
CADL
5 Mar 24
in an ongoing investigator-sponsored phase 1 clinical trial in recurrent high-grade glioma (HGG). Finally, Candel's enLIGHTEN™ Discovery Platform
31tbj
CADL
28 Feb 24
and expedite the review of medicines that can treat serious conditions, Fast Track Designation offers an investigational medicine eligibility for more frequent
- Prev
- 1
- Next